GEN Exclusives

More »

GEN News Highlights

More »
May 1, 2007

Alethia and Emerillon to Tackle Bone Diseases

  • Alethia Biotherapeutics and Emerillon Therapeutics signed a collaborative research agreement to work together on bone-related diseases such as osteoporosis. The companies will conduct a discovery and functional validation program to identify new drug candidates.

    According to the deal, Emerillon will provide a list of genetic loci that are associated with an osteoporotic phenotype in mice. In return, Alethia will generate bone-specific cDNA libraries to help identify these genes. It also will conduct cell-based validation studies to determine the functional relevance of the genes provided.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »